Seelos Therapeutics Inc (SEEL) - Koefisien utang jangka dawa marang modal

Seelos Therapeutics (SEEL) is a research business developing treatments for CNS pathologies and rare neuropathies, which has earned it recognition within the scientific community. However, the company is currently in a deep crisis due to a series of trial failures, leading to financial collapse and the risk of delisting. This price chart, serving as the primary valuation tool where the indicator equals 0.00, accounts for the potential implementation of intranasal ketamine.

For Seelos Therapeutics (SEEL), which develops drugs for suicidal disorders, the long-term debt structure ratio reflects the financial stability of its biotech model. This indicator measures the proportion of liabilities with a maturity of over one year relative to equity. The calculation is based on the ratio of long-term loans to net asset value. This allows for an assessment of the company's dependence on external financing while creating innovative molecules. An increase in this metric signals rising credit risks.